# Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

> **NCT02307240** · PHASE1 · COMPLETED · sponsor: **Curis, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Triple-Negative Breast Cancer
- High-grade Serous Ovarian Cancer
- Solid Tumors
- NUT Midline Carcinoma

## Interventions

- **DRUG:** CUDC-907

## Key facts

- **NCT ID:** NCT02307240
- **Lead sponsor:** Curis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307240, "Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02307240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*